News & views
Our collective understanding of mental health is increasing all the time, with advances in neuroscience, psychotherapy, psychopharmacology and digital platforms.
For media inquiries, contact us at media@compasspathways.com
December 08, 2022
COMP360 psilocybin therapy shows potential in open-label study in type II bipolar disorder presented at ACNP
November 03, 2022
COMPASS Pathways Announces Third Quarter 2022 Financial Results and Business Highlights
November 03, 2022
COMPASS Pathways announces publication of phase 2b study of COMP360 psilocybin therapy for treatment-resistant depression in The New England Journal of Medicine
October 27, 2022
COMPASS Pathways plc to announce third quarter 2022 financial results on 3 November 2022
October 12, 2022
COMPASS Pathways Announces Phase 3 Pivotal Program Design for COMP360 in Treatment Resistant Depression at Capital Markets Day
October 04, 2022
COMPASS Pathways to Hold Virtual Capital Market Day on 12 October 2022
August 04, 2022
COMPASS Pathways plc announces second quarter 2022 financial results and business highlights
August 02, 2022
COMPASS Pathways Announces Grant of Inducement Award for Newly Appointed Chief Executive Officer Pursuant to Nasdaq Listing Rule 5635(c)(4)
July 28, 2022
COMPASS Pathways launches phase 2 clinical trial of psilocybin therapy in anorexia nervosa
July 19, 2022
COMPASS Pathways appoints Kabir Nath as Chief Executive Officer
July 19, 2022
Letter from Kabir Nath, our new CEO from August 1, 2022
May 23, 2022
COMPASS Pathways presents largest ever study of psilocybin therapy, at American Psychiatric Association annual meeting
May 10, 2022
COMPASS Pathways plc announces first quarter 2022 financial results and business highlights
May 09, 2022
COMPASS Pathways to fund study of COMP360 psilocybin in autistic adults
May 03, 2022
COMP360 psilocybin therapy shows potential in exploratory open-label studies for anorexia nervosa and severe treatment-resistant depression
April 20, 2022
COMPASS Pathways partners with One Mind to fund Rising Star Awards for the next generation of mental health researchers
October 20, 2021
Open-label study of COMP360 psilocybin therapy for depression in cancer patients demonstrates feasibility of simultaneous psilocybin administration in small groups
October 19, 2021
COMPASS Pathways is granted new US patent for crystalline psilocybin
March 09, 2021
COMPASS Pathways plc announces financial results and business highlights for fourth quarter and year-end 2020